Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable lipoprotein aminopeptidase LpqL | 0.0058 | 0.0429 | 0.5 |
Echinococcus multilocularis | endoplasmic reticulum metallopeptidase 1 | 0.0058 | 0.0429 | 0.0429 |
Trypanosoma brucei | glutaminyl cyclase, putative | 0.0058 | 0.0429 | 0.5 |
Trypanosoma cruzi | glutaminyl cyclase, putative | 0.0058 | 0.0429 | 0.5 |
Echinococcus granulosus | endoplasmic reticulum metallopeptidase 1 | 0.0058 | 0.0429 | 0.0429 |
Schistosoma mansoni | glutaminyl cyclase (M28 family) | 0.0365 | 1 | 1 |
Toxoplasma gondii | hypothetical protein | 0.0058 | 0.0429 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0058 | 0.0429 | 0.5 |
Trichomonas vaginalis | Clan MH, family M28, aminopeptidase S-like metallopeptidase | 0.0058 | 0.0429 | 0.5 |
Leishmania major | glutaminyl cyclase, putative | 0.0058 | 0.0429 | 0.5 |
Brugia malayi | FXNA | 0.0058 | 0.0429 | 0.0429 |
Loa Loa (eye worm) | hypothetical protein | 0.0365 | 1 | 1 |
Onchocerca volvulus | Glutaminyl cyclase homolog | 0.0365 | 1 | 1 |
Schistosoma mansoni | Fxna peptidase (M28 family) | 0.0058 | 0.0429 | 0.0429 |
Echinococcus granulosus | glutaminyl peptide cyclotransferase | 0.0365 | 1 | 1 |
Trypanosoma cruzi | glutaminyl cyclase, putative | 0.0058 | 0.0429 | 0.5 |
Echinococcus multilocularis | glutaminyl peptide cyclotransferase | 0.0365 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0058 | 0.0429 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.0058 | 0.0429 | 0.5 |
Mycobacterium ulcerans | lipoprotein aminopeptidase LpqL | 0.0058 | 0.0429 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0058 | 0.0429 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.0429 | 0.0429 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.0429 | 0.0429 |
Brugia malayi | leucyl aminopeptidase | 0.0058 | 0.0429 | 0.0429 |
Loa Loa (eye worm) | leucyl aminopeptidase | 0.0058 | 0.0429 | 0.0429 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0058 | 0.0429 | 0.5 |
Brugia malayi | nicalin | 0.0058 | 0.0429 | 0.0429 |
Echinococcus multilocularis | endoplasmic reticulum metallopeptidase 1 | 0.0058 | 0.0429 | 0.0429 |
Schistosoma mansoni | NAALADASE L peptidase (M28 family) | 0.0058 | 0.0429 | 0.0429 |
Echinococcus granulosus | endoplasmic reticulum metallopeptidase 1 | 0.0058 | 0.0429 | 0.0429 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.0429 | 0.0429 |
Schistosoma mansoni | nicalin (M28 family) | 0.0058 | 0.0429 | 0.0429 |
Schistosoma mansoni | glutaminyl-peptide cyclotransferase-related | 0.0058 | 0.0429 | 0.0429 |
Mycobacterium tuberculosis | Conserved protein | 0.0058 | 0.0429 | 0.5 |
Echinococcus multilocularis | n acetylated alpha linked acidic dipeptidase 2 | 0.0058 | 0.0429 | 0.0429 |
Loa Loa (eye worm) | hypothetical protein | 0.0058 | 0.0429 | 0.0429 |
Toxoplasma gondii | peptidase, M28 family protein | 0.0058 | 0.0429 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | Antibacterial activity against Escherichia coli at 100 ug after 24 hr by cup-plate method | ChEMBL. | No reference | |
Activity (functional) | = 10.52 % | Antimalarial activity against Plasmodium yoelii N-67 infected Swiss mouse assessed as parasitemia at 200 mg/kg, ip qd administered 4 days measured 24 hr post last treatment (Rvb = 12.36 +/- 1.14 %) | ChEMBL. | No reference |
Activity (functional) | = 16.8 % | Antimalarial activity against Plasmodium yoelii N-67 infected Swiss mouse assessed as parasitemia at 200 mg/kg, ip qd administered 4 days measured on day 7 (Rvb = 19.5 +/- 0.76 %) | ChEMBL. | No reference |
MST (functional) | = 6.8 day | Antimalarial activity against Plasmodium yoelii N-67 infected Swiss mouse assessed as mean survival time at 200 mg/kg, ip qd administered 4 days measured 24 hr post last treatment (Rvb = 8.2 +/- 0.86 days) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.